RecruitingNot ApplicableNCT07437911

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs

Sponsor

Athletic Greens International

Enrollment

120 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

nutrition status Gastrointestinal Microbiome GLP - 1 Nutrition Intake

Summary

This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut microbiome among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users.

Eligibility

Min Age: 18 YearsMax Age: 59 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying AG1 - Nutritional Supplement and Placebo for people with glp - 1, gastrointestinal microbiome, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 59 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAG1 - Nutritional Supplement

AG1 - Nutritional Supplement

DIETARY_SUPPLEMENTPlacebo

Maltodextrin Placebo

Locations(1)

Citruslabs

Santa Monica, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07437911

Related Trials

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

NCT076055721 location

Slowly Digestible Carbohydrates for GLP-1 Secretion

NCT075725131 location